SEC Form 4 · accession 0000950138-17-000703
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J Martin Carroll
Director
Period of report
Oct 1, 2017
Accepted (ET)
Oct 3, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Oct 1, 2017 | F | 476 | $37.37 | D | 18,423 | D | |
| Ordinary SharesF1 | holding | — | — | — | 131 | I | By Grantor Retained Annuity Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 9,458 shares which were contributed by the reporting person to a grantor retained annuity trust in August 2016 and 9,327 shares distributed in satisfaction of an annuity by the grantor retained annuity trust to the reporting person in September 2017. These transactions were exempt from reporting pursuant to Rule 16a-13.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.